Status:
TERMINATED
Docusate/Senna for the Treatment of Diabetic Gastroparesis
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Diabetic Gastroparesis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The aim of the study is to evaluate the efficacy of the stimulant laxative Senokot-S® for the treatment of diabetic gastroparesis. Senokot-S, and its metabolites, are thought to produce peristalsis, d...
Eligibility Criteria
Inclusion
- Age 18-75 years, male and non-pregnant, non-lactating females
- Diagnosis of type 1 or type 2 diabetes mellitus
- Clinical diagnosis of diabetic gastroparesis
Exclusion
- Diagnosed idiopathic gastroparesis
- A history or inflammatory bowel disease, such as Crohn's disease or ulcerative colitis
- A history of bowel obstruction, current unexplained abdominal pain, or undiagnosed rectal bleeding
- Gastrointestinal cancer
- Any active cancer
- Prior gastric surgery
- End-stage heart disease, liver disease, lung disease
- Known or suspected drug abuse
- Any condition requiring use of daily narcotics
- Concurrent usage of mineral oil or products containing mineral oil
- Current or recent (within the last 3 months) usage of Senokot-S, docusate or senna
Key Trial Info
Start Date :
April 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 17 2018
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT03342157
Start Date
April 2 2018
End Date
August 17 2018
Last Update
October 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aurora Health Care
Milwaukee, Wisconsin, United States, 53202